18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma

Clinical Nuclear Medicine - Tập 44 Số 8 - Trang 605-611 - 2019
Trond Velde Bogsrud1,2,3,4,5, Ayca Muftuler Løndalen3, Petter Brandal3,6,7, Henning Leske1, Ioannis Panagopoulos7, Per Borghammer1,4, Tore Bach‐Gansmo3
1Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus
2Department of Nuclear Medicine and PET-Centre, University Hospital of North Norway, Tromso
3Department of Nuclear Medicine, Oslo University Hospital, Oslo, Norway
4The Faculty of Health, Aarhus University, Aarhus, Denmark
5Trond V. Bogsrud, MD, PhD, University Hospital of North Norway, Sykehusvegen 38, 9019 Tromsø, Norway. E-mail: [email protected].
6Department of Oncology, Oslo University Hospital
7Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Oslo University Hospital

Tóm tắt

Purpose To retrospectively investigate the uptake of 18F-fluciclovine on PET/CT in patients with suspected recurrent high-grade glioma (HGG). Methods Twenty-one patients were included. The standard of truth was histopathologic interpretation if available. When histopathology was not available or rebiopsy did not show signs of malignancy, clinical follow-up including MRI and clinical outcome was considered the standard of truth. Results All 21 patients met the reference standard of either histopathologic proof of HGG recurrence (n = 10) or disease progression clinically and with tumor growth corresponding to the primary tumor sites on follow-up MRI (n = 11). Median time from PET/CT to death was 5 months (range, 1–20 months). Median time from primary diagnosis to death was 14.5 months (range, 6 to >400). Average SUVmax of the lesions was 8.3 ± 5.3 (SD) and 0.34 ± 0.13 for normal brain tissue. Median lesion-to-background ratio was 21.6 (range, 3.1–84.4). In 4 patients, 18F-fluciclovine PET/CT detected small satellite tumors that had not been reported on MR. Conclusions The uptake of 18F-fluciclovine in clinically and/or histopathologically confirmed recurrent HGG is high compared with the uptake reported for other amino acid PET tracers. Because of the high tumor uptake and thus high tracer contrast, small satellite tumors with a diameter below usual reported PET spatial resolution and not reported on MRI were detected in 4 patients. As no patients with confirmed treatment-related changes were included, we cannot as of yet ascertain the ability of 18F-fluciclovine PET to discriminate between recurrent HGG and treatment-related changes, for example, pseudoprogression and radionecrosis.

Từ khóa


Tài liệu tham khảo

2013, Glioblastoma and other malignant gliomas: a clinical review, JAMA, 310, 1842, 10.1001/jama.2013.280319

2016, High-grade glioma management and response assessment—recent advances and current challenges, Curr Oncol, 23, 383, 10.3747/co.23.3082

2009, Neuroimaging in neuro-oncology, Neurotherapeutics, 6, 465, 10.1016/j.nurt.2009.05.002

2017, Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis, Eur Radiol, 27, 4129, 10.1007/s00330-017-4789-9

2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330

2017, Pseudoprogression after glioma therapy: an update, Expert Rev Neurother, 17, 1109, 10.1080/14737175.2017.1375405

2002, Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas, Int J Radiat Oncol Biol Phys, 53, 58, 10.1016/S0360-3016(01)02819-X

2005, O-(2-[18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas, Brain, 128, 678, 10.1093/brain/awh399

2014, Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors, Mol Imaging, 13, 1

2016, The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy, Neuroimage Clin, 13, 386

2017, Amino acid PET and MR perfusion imaging in brain tumours, Clin Transl Imaging, 5, 209, 10.1007/s40336-017-0225-z

2017, Advances in neuro-oncology imaging, Nat Rev Neurol, 13, 279, 10.1038/nrneurol.2017.44

2017, Comparison of (18)F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study, Eur J Nucl Med Mol Imaging, 44, 2257, 10.1007/s00259-017-3812-3

2016, Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas, Neuro Oncol, 18, 1199, 10.1093/neuonc/now058

2016, Assessment of brain tumor response: RANO and its offspring, Curr Treat Options Oncol, 17, 35, 10.1007/s11864-016-0413-5

2001, Radiolabeled amino acids: basic aspects and clinical applications in oncology, J Nucl Med, 42, 432

1999, Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors, J Nucl Med, 40, 331

2013, trans-1-Amino-3-18F-fluorocyclobutanecarboxylic acid (anti–18F-FACBC) is a feasible alternative to 11C-methyl-l-methionine and magnetic resonance imaging for monitoring treatment response in gliomas, Nucl Med Biol, 40, 808, 10.1016/j.nucmedbio.2013.04.007

2013, Comparative evaluation of transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid and l-[methyl-11C]methionine in human glioma cell lines, Brain Res, 1535, 24, 10.1016/j.brainres.2013.08.037

2014, Differences in transport mechanisms of trans-1-amino-3-F-18fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with l-[methyl-11C]methionine and 2-deoxy-2-F-18fluoro-d-glucose, Mol Imaging Biol, 16, 322, 10.1007/s11307-013-0693-0

2013, Pilot study of the utility of the synthetic PET amino-acid radiotracer anti–1-amino-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions, Mol Imaging Biol, 15, 633, 10.1007/s11307-012-0606-7

2014, Anti–1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease, J Nucl Med, 55, 1986, 10.2967/jnumed.114.143628

2016, Anti–3-18F-FACBC (18F-fluciclovine) PET/CT of breast cancer: an exploratory study, J Nucl Med, 57, 1357, 10.2967/jnumed.115.171389

2009, Initial experience with the radiotracer anti–1-amino-3-F-18fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC) with PET in renal carcinoma, Mol Imaging Biol, 11, 434, 10.1007/s11307-009-0220-5

2016, Phase IIa clinical study of [(18)F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors, Ann Nucl Med, 30, 608, 10.1007/s12149-016-1102-y

2017, Diagnostic performance and safety of positron emission tomography using 18F-fluciclovine in patients with clinically suspected high- or low-grade gliomas: a multicenter phase IIb trial, Asia Ocean J Nucl Med Biol, 5, 10

2003, Improved synthesis of anti–F-18FACBC: improved preparation of labeling precursor and automated radiosynthesis, Appl Radiat Isot, 58, 657, 10.1016/S0969-8043(03)00029-0

2009, Stereoselective synthesis and biological evaluation of syn-1-amino-3-F-18fluorocyclobutyl-1-carboxylic acid as a potential positron emission tomography brain tumor imaging agent, Bioorg Med Chem, 17, 1982, 10.1016/j.bmc.2009.01.032

2017, Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective, Clin Transl Imaging, 5, 135, 10.1007/s40336-016-0213-8

2012, Improved survival time trends for glioblastoma using the SEER 17 population-based registries, J Neurooncol, 107, 207, 10.1007/s11060-011-0738-7

2015, German Glioma Network. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM, Neurology, 84, 710, 10.1212/WNL.0000000000001262

2017, Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment?, EJNMMI Res, 7, 48, 10.1186/s13550-017-0295-y

2016, Serial 18F-FET PET imaging of primarily 18F-FET-negative glioma: does it make sense?, J Nucl Med, 57, 1177, 10.2967/jnumed.115.171033

2017, Diagnosis of brain tumors using amino acid transport PET imaging with 18F-fluciclovine: a comparative study with l-methyl-11C-methionine PET imaging, Asia Ocean J Nucl Med Biol, 5, 85

2017, Minimum lesion detectability as a measure of PET system performance, EJNMMI Phys, 4, 13, 10.1186/s40658-017-0179-2

2006, Structure of the blood-brain barrier and its role in the transport of amino acids, J Nutr, 136, 218S

2015, Evaluation of trans-1-amino-3-F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings, Nucl Med Biol, 42, 664, 10.1016/j.nucmedbio.2015.04.008

2017, Point-spread function reconstructed PET images of sub-centimeter lesions are not quantitative, EJNMMI Phys, 5, 4

2017, Dynamic O-(2-18F-fluoroethyl)-l-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy, Neuro Oncol, 19, 281

2012, MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?, Eur J Nucl Med Mol Imaging, 39, 1021, 10.1007/s00259-012-2109-9

2007, FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading, Eur J Nucl Med Mol Imaging, 34, 1933, 10.1007/s00259-007-0534-y

2018, Glioma epigenetics: From subclassification to novel treatment options, Semin Cancer Biol, 51, 50, 10.1016/j.semcancer.2017.11.010

Thông tin
Thông tin xuất bản

Clinical Nuclear Medicine

Tập 44 Số 8

605-611

Thông tin tác giả